Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 198

The DOI matches its Crossref record.

Recurrence After Treatment of Micropapillary Thyroid Cancer

Ross, Douglas S., Litofsky, Danielle, Ain, Kenneth B., Bigos, Thomas, Brierley, James D., Cooper, David S., Haugen, Bryan R., Jonklaas, Jacqueline, Ladenson, Paul W., Magner, James, Robbins, Jacob, Skarulis, Monica C., Steward, David L., Maxon, Harry R., Sherman, Steven I.·2009·Thyroid

Abstract

BACKGROUND: Despite very low mortality associated with micropapillary thyroid cancer, locoregional recurrence is common and controversy exists regarding optimal surgical treatment and the role of adjunctive radioiodine. METHODS: The National Thyroid Cancer Treatment Cooperative Study Group Registry was analyzed for recurrences in patients with unifocal versus multifocal micropapillary cancer, with or without nodal disease, depending upon the extent of surgery and the use of adjunctive radioiodine. Six hundred eleven patients considered disease-free after initial therapy were followed for 2572 person-years. RESULTS: Thirty patients (6.2%) had recurrences detected at a mean 2.8 years after primary treatment. Recurrences did not differ between patients with unifocal and multifocal disease overall; however, among patients who received less than a near-total thyroidectomy (NTT), those with multifocal disease had more recurrences than those with unifocal disease (18% vs. 4%, p = 0.01). Patients with multifocal disease who had a total (T) or NTT trended toward fewer recurrences than those undergoing less than an NTT (6% vs. 18%, p = 0.058). In patients who did not receive radioiodine therapy, recurrence was more common in patients with multifocal disease versus unifocal disease (7% vs. 2%, p = 0.02). However, radioiodine did not reduce recurrences in patients with multifocal disease or patients with positive nodes. Patients with positive nodes had more recurrences than node-negative patients regardless of surgical extent or use of radioiodine. CONCLUSIONS: Patients with micropapillary multifocal disease have a reduced risk of recurrence after a T/NTT compared with less surgery. A randomized, controlled trial is necessary and feasible to determine if radioiodine ablation of thyroid remnants is advantageous in patients with intrathyroidal micropapillary cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/thy.2008.0407

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 198

Metadata

Authors
Ross, D. S., Litofsky, D., Ain, K. B., Bigos, T., Brierley, J. D., Cooper, D. S., Haugen, B. R., Jonklaas, J., Ladenson, P. W., Magner, J., Robbins, J., Skarulis, M. C., Steward, D. L., Maxon, H. R., & Sherman, S. I.
Venue
Thyroid
Published
2009-10
Volume
19
Issue
10
Pages
1043-1048
ISSN
  • 1050-7256 (ISSN-L)
  • 1557-9077
OpenAlex
W1999325012
Cited by
198
References
0
FWCI
11.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recurrence After Treatment of Micropapillary Thyroid Cancer. https://app.cochat.ai/papers/10.1089/thy.2008.0407
The paper
Ross, D. S., Litofsky, D., Ain, K. B., Bigos, T., Brierley, J. D., Cooper, D. S., Haugen, B. R., Jonklaas, J., Ladenson, P. W., Magner, J., Robbins, J., Skarulis, M. C., Steward, D. L., Maxon, H. R., & Sherman, S. I. (2009). Recurrence After Treatment of Micropapillary Thyroid Cancer. Thyroid. https://doi.org/10.1089/thy.2008.0407

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.